paroxetine has been researched along with Myocardial Infarction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Babongo Bosombo, F; Bernhard, B; Dobner, S; Fürholz, M; Hunziker, L; Lanz, J; Losdat, S; Pilgrim, T; Reusser, N; Siontis, GCM; Stortecky, S; Vollenbroich, R; Windecker, S | 1 |
| Bøtker, HE; Johnsen, J; Kristiansen, SB; Lassen, TR; Nielsen, JM; Ringgaard, S | 1 |
| Cai, H; Gong, X; Guo, Y; Han, W; Jiang, P; Liao, D; Liu, M | 1 |
| Chen, X; Chuprun, JK; Feldman, AM; Gao, E; Koch, WJ; Schumacher, SM; Tesmer, JJ; Zhu, W | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Babak, S; Bergman, U; Bertilsson, L; Boldueva, S; Burbello, A; Goryachkina, K | 1 |
1 trial(s) available for paroxetine and Myocardial Infarction
| Article | Year |
|---|---|
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Area Under Curve; Bradycardia; Cytochrome P-450 CYP2D6; Depression; Dose-Response Relationship, Drug; Drug Interactions; Female; Genotype; Heart Rate; Humans; Hypotension, Orthostatic; Male; Metoprolol; Middle Aged; Myocardial Infarction; Paroxetine | 2008 |
5 other study(ies) available for paroxetine and Myocardial Infarction
| Article | Year |
|---|---|
Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition in Patients With Acute Anterior Myocardial Infarction: Final 1-Year Outcomes of the Randomized CARE-AMI Trial.
Topics: Anterior Wall Myocardial Infarction; GTP-Binding Proteins; Humans; Myocardial Infarction; Paroxetine; Randomized Controlled Trials as Topic | 2022 |
Effect of paroxetine on left ventricular remodeling in an in vivo rat model of myocardial infarction.
Topics: Animals; Antioxidants; Echocardiography; Magnetic Resonance Imaging; Male; Myocardial Infarction; Paroxetine; Rats; Rats, Wistar; Reactive Oxygen Species; Selective Serotonin Reuptake Inhibitors; Ventricular Remodeling | 2017 |
Alleviating Effect of Antidepressant Treatment on Psychiatric Symptoms and Cardiac Conditions in a Patient with Coronary Slow Flow Comorbid with Depression and Anxiety.
Topics: Antidepressive Agents; Anxiety; Comorbidity; Depression; Female; Humans; Middle Aged; Myocardial Infarction; Paroxetine | 2018 |
Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Fibrosis; G-Protein-Coupled Receptor Kinase 2; Heart Failure; Hemodynamics; Male; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Paroxetine; Receptors, Adrenergic, beta; Translational Research, Biomedical; Ventricular Remodeling | 2015 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |